XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.44
+0.28 (+12.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.16
Open2.16
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range2.12 - 2.44
52 Week Range1.33 - 4.44
Volume14,122,990
Avg. Volume1,677,542
Market Cap303.319M
Beta2.12
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateAug 7, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
Trade prices are not sourced from all markets
  • Business Wire5 days ago

    22nd Century Conducts Three Short-Term Studies in Support of the Company’s MRTP Application to the FDA

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine Content tobacco, announced that the Company has initiated three short-term studies investigating the behavioral and biochemical responses to the Company’s proprietary Very Low Nicotine Content tobacco. 22nd Century scientists will submit to the FDA the data collected from these studies as part of the Company’s revised and enhanced Modified Risk Tobacco Product (MRTP) application for “BRAND A” Very Low Nicotine Content cigarettes.

  • Business Wire12 days ago

    22nd Century Group to be Added to Russell 2000, Russell 3000, and Russell Global Indexes

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today that the Company will be added to the Russell 2000, Russell 3000, and Russell Global Indexes when FTSE Russell (Russell) reconstitutes its U.S. and global equity indexes on June 22, 2018. Russell’s preliminary announcement of its annual reconstitution of these Indexes, which includes 22nd Century Group, was posted on the Russell website on Friday, June 8, 2018, after the U.S. stock market closed.

  • ACCESSWIRE20 days ago

    Free Technical Research on Versartis and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).

  • Business Wire21 days ago

    22nd Century to Present to Institutional Investors at the Citi 2018 Small & Mid Cap Conference

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, today announced that the Company will present at the Citi 2018 Small & Mid Cap Conference at the Lotte New York Palace Hotel, New York, NY on Wednesday, June 6, 2018 at 8:00AM Eastern Time. Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group, will deliver a formal presentation to institutional investors and will discuss the Company’s recent business highlights and updates. Mr. Sicignano will also be available for one-on-one meetings with investors at the conference.

  • Business Wire27 days ago

    Altria, Reynolds, Lorillard, and Philip Morris Ordered to Issue Corrective Statements on Nicotine Addiction; 22nd Century’s Proprietary VLN (TM) Tobacco Called “Minimally or Non-Addictive”

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced that on May 1, 2018, a federal court ordered Altria, R.J. Reynolds Tobacco, Lorillard, and Philip Morris USA to issue statements to correct marketing that deliberately deceived the public about the addictiveness and health risks of smoking.

  • Benzingalast month

    Cannabis Hedge Fund Managers On The Two Biggest Problems Marijuana Businesses Face

    A few weeks ago, Benzinga had the chance to visit the offices of Poseidon Asset Management, a San Francisco-based cannabis-focused long/short hedge fund with more than $40 million in assets under management. Co-founder and managing partner Emily Paxhia mentioned and her brother and partner Morgan Paxhia have helped turn around multiple companies.

  • Business Wirelast month

    Public Health Leaders Urge FDA to Issue Final Rule for Reducing Nicotine in Cigarettes by March 2019

    22nd Century Group, Inc. (NYSE MKT: XXII), a plant biotechnology company that is a leader in tobacco harm reduction and Very Low Nicotine tobacco, announced today that 41 public health and medical organizations wrote an open letter to Dr. Scott Gottlieb, Commissioner of the U.S. Food and Drug Administration (FDA), urging the FDA to quickly implement its plan to reduce nicotine in cigarettes to minimally or non-addictive levels. 22nd Century is the only company in the world that has grown commercial crops of proprietary tobacco with nicotine levels of just 0.4mg per gram of tobacco – a 95% reduction in nicotine as compared to tobacco used in conventional cigarettes.

  • Benzingalast month

    Marijuana In College: Why Universities Are Offering Cannabis-Focused Classes (And Where You Can Find Them)

    The legal cannabis industry is growing at an unprecedented pace. This figure is expected to surge to roughly $35 billion by 2022, GreenWave Advisors managing partner Matt Karnes told Benzinga in a recent conversation. “We expect that by 2022, all states will have implemented either a medical only or fully legal marijuana market,” he said.

  • Push to add women to WNY boards gains momentum
    American City Business Journalslast month

    Push to add women to WNY boards gains momentum

    A review of annual proxy statements filed in 2007 shows that women held 5 percent of board seats at the region’s publicly traded companies that year. By 2017 that figure had crept up to about 10.5 percent.

  • Why 22nd Century Group Inc (NYSEMKT:XXII) Could Be A Buy
    Simply Wall St.2 months ago

    Why 22nd Century Group Inc (NYSEMKT:XXII) Could Be A Buy

    22nd Century Group Inc (AMEX:XXII), a tobacco company based in United States, saw a decent share price growth in the teens level on the AMEX over the last few months.Read More...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Alcoa, FedEx, 22nd Century Group, Aspen Technology, Yum! Brands, and NVR — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, May 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alcoa ...

  • Associated Press2 months ago

    22nd Century: 1Q Earnings Snapshot

    The Clarence, New York-based company said it had profit of 1 cent per share. The plant biotechnology company posted revenue of $6.1 million in the period. The company's shares closed at $2.02. A year ago, ...

  • Business Wire2 months ago

    22nd Century Files 2018 First Quarter Report

    22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine tobacco, and hemp/cannabis research, announced today the Company’s first quarter 2018 financial results. 22nd Century will provide a business update for investors on a conference call to be held Friday, May 4, 2018, at 4:00 PM (Eastern Time). Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group, together with John T. Brodfuehrer, Chief Financial Officer, will conduct the call.

  • Business Wire2 months ago

    22nd Century Committed to Advancing FDA’s Nicotine Mandate

    22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Company is committed to working collaboratively with the U.S.

  • Business Wire2 months ago

    Food and Drug Law Institute Publishes Public Policy Article by 22nd Century’s Dr. James Swauger

    22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the Food and Drug Law Institute (FDLI) has published an article by Dr. James Swauger, Senior Vice President of Science and Regulatory Affairs at 22nd Century. In this matter-of-fact public policy analysis, Dr. Swauger points out that since it is universally accepted that nicotine is the primary addictive component of cigarettes, the tobacco industry and public health officials should logically support the nicotine reduction plan proposed by the U.S. Food and Drug Administration (FDA).

  • Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals
    Motley Fool2 months ago

    Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals

    These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?

  • Benzinga3 months ago

    4 Stocks To Watch Following The FDA's Proposal To Lower Nicotine In Cigarettes

    What Happened The U.S. Food and Drug Administration announced March 15 an Advance Notice of Proposed Rulemaking (ANPRM) to procure information to help set the maximum nicotine level for cigarettes to non-addictive ...

  • Business Wire3 months ago

    FDA Publishes Advance Notice of Proposed Rulemaking (ANPRM) on Lowering Nicotine in Cigarettes

    22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the U.S. Food and Drug Administration has published in the Federal Register the FDA’s Advance Notice of Proposed Rulemaking to lower nicotine in cigarettes to minimally or non-addictive levels.

  • Why Isn't This Marijuana Stock Booming? (Hint: The Answer Has Nothing to Do With Weed)
    Motley Fool3 months ago

    Why Isn't This Marijuana Stock Booming? (Hint: The Answer Has Nothing to Do With Weed)

    Tobacco, not marijuana, is this company's main focus now. But the reason the stock isn't soaring is a little complicated.

  • Investopedia3 months ago

    Pot Stock Winners of the Week

    Here are the week's four biggest marijuana stock winners.

  • Business Wire4 months ago

    22nd Century Group Files 2017 Annual Report and Announces Conference Call to Provide Business Update

    22nd Century Group, Inc. , a plant biotechnology company that is focused on tobacco harm reduction and hemp research, announced today that the Company filed its 2017 Annual Report on Form 10-K with the U.S.

  • Are 22nd Century Group Inc’s (NYSEMKT:XXII) Interest Costs Too High?
    Simply Wall St.4 months ago

    Are 22nd Century Group Inc’s (NYSEMKT:XXII) Interest Costs Too High?

    While small-cap stocks, such as 22nd Century Group Inc (AMEX:XXII) with its market cap of US$311.38M, are popular for their explosive growth, investors should also be aware of their balanceRead More...

  • 22nd Century Group Inc (NYSEMKT:XXII): Does -2.91% Earnings Drop In A Year Reflect The Long-Term Trend?
    Simply Wall St.4 months ago

    22nd Century Group Inc (NYSEMKT:XXII): Does -2.91% Earnings Drop In A Year Reflect The Long-Term Trend?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Business Wire4 months ago

    17th World Conference on Tobacco or Health Will Feature Discussion on the FDA’s Plan to Dramatically Reduce Nicotine in Cigarettes

    22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announces the nicotine reduction mandate planned by the U.S.